Laddar...
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
AIM: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. METHODS: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption p...
Sparad:
| I publikationen: | Lung Cancer Manag |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Future Medicine Ltd
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7110588/ https://ncbi.nlm.nih.gov/pubmed/32256712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2019-0011 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|